Bli medlem
Bli medlem

Du är här



Helsinki, 20 August 2015 at 8:00 am

Company Highlights, January - June 2015

* Phase III multi-centre trial in the US for stroke therapy is progressing
according to plans; successfully enrolling patients on time with first
milestone interim analysis expected in Q3 2015
* January - June 2015 revenue growth of 55.4 percent compared to first half
of 2014
* Appointment of Olli Riikkala as Chairman of the Board of Directors, and
Juliet Thompson as a new independent non-executive director

Status of clinical development

Nexstim's Navigated Brain Therapy (NBT®) System is currently in the
development phase. The Company is currently building clinical evidence by
conducting a clinical Phase III multi-centre clinical trial to demonstrate
the effectiveness of the use of Nexstim's NBT®System in post-acute stroke
therapy. The clinical trial is progressing according to plans and the first
interim analysis milestone is estimated to be reached in Q3 2015 with a
second interim analysis in Q1 2016. The final analysis is expected to be
ready by the end of 2016.

CEO Janne Huhtala's review

The first half of 2015 contained several successes, including the positive
progress made in the Phase III clinical trial using our NBT®System and
traction of Navigated Brain Stimulation (NBS). We are also pleased with the
momentum of continued interest from academics and clinicians in Nexstim's
technology and software.

Nexstim continued to progress its ongoing Phase III, two year, multi-centre
clinical trial for the use of Nexstim's NBT®System in post-acute stroke
therapy in 12 different rehabilitation centres in the US. The trial is on
track for completion by end 2016 and we estimate that we will announce the
interim analysis in Q3 2015. The company has ongoing dialogue with FDA
regarding the 510(k) De Novo submission.

Nexstim has been targeting NBS system sales to strategic customers such as
teaching hospitals and universities with a strong KOL presence and supported
by capital equipment investment sales models. Medical research from these
important centres continues to be published internationally by Nexstim
affiliates, extolling the benefits of NBS mapping in neurosurgery and
neurosurgical planning, and demonstrating the value of NBS to neurosurgery
outcomes and workflows, supporting the wider adoption of this technology and

Nexstim revenues EUR 643.2 thousand have increased by 55.4 percent compared to
the equivalent period in 2014 (EUR 413.9 thousand) due to an increase in NBS
system sales revenue in Europe and the Middle-East. Sales of NBS systems in
US markets was disappointing, mainly due to customers postponing capital
investment decisions, causing a consequential lumpiness in revenue
expectations. We estimate that the sales pipeline for H2 2015 will continue
to be strong, however, due to potential delays in the US market, the overall
full year 2015 NBS sales growth rate may be affected.

Nexstim ended the first half of 2015 with a cash position of EUR 6.1 million.
Due to the possible lower level of NBS sales in US and slightly higher than
earlier estimated Phase III trial costs, the current cash and cash generated
from sales is estimated to be sufficient to finance the company's existing
clinical development trials for the first two milestones (Q3 2015 and Q1
2016) and pre-commercialisation activities.

With the potential for successful Phase III trial milestones, Nexstim is
preparing for the possibility of advancing the NBT®system commercialisation
and, during 2015, Nexstim has actively engaged with the investment community
and has received a lot of positive interest.

Nexstim also was very pleased to announce the appointment of Olli Riikkala as
Chairman of the Board of Directors, and Juliet Thompson as a new Board
member, at the Annual General Meeting, adding strength to the Board and
aligning it to Nexstim's international growth strategy.

Key performance indicators

| EUR in thousands 1-6/2015 1-6/2014 1-12/2014 |
| |
| |
| 6 months 6 months 12 months |
| Net sales 643.2 413.9 2,210.4 |
| Personnel expenses -1,906.1 -1,641.9 -3,660.2 |
| Depreciation and amortisation -168.7 -125.3 -377.4 |
| Other operating expenses -3,422.9 -1,672.3 -5,498.5 |
| Profit/ -Loss for the period -4,555.0 -5,127.3 -10,445.4 |
| Earnings per share (EUR)* -0.64 -1.44 -2.37 |
| Diluted earnings per share (EUR)* -0.58 -1.34 -2.16 |
| Cash flows from operating activities -5,275.3 -2,508.1 -7,785.2 |
| Cash in hand and at banks 6,071.1 1,522.1 11,483.7 |
| Total equity 3,712.0 -4,077.3 8,589.9 |
| Equity ratio (%) 50.44 -87.19 65.29 |
| Number of shares in the end of the period (pcs)* 7,130,758 3,685,290 7,130,758 |
| Average number of shares during the period (pcs)* 7,130,758 3,561,908 4,406,572 |
| Diluted number of shares in the end of the period (pcs)* 7,917,698 4,016,936 7,917,698 |
| Diluted average number of shares during the period (pcs)* 7,917,698 3,836,910 4,826,140 |
| |
*The number of Shares and subscription price have been adjusted to take
account the effect of the merging of the share classes and share split on 29
September 2014, where the number of Shares was increased 14-fold

Future Outlook

Based on its business forecast and sensitivity analysis the company expects
its net sales from the sale of NBS Systems (Pre-Surgical Mapping, PSM) to
grow during financial year 2015 and operating profit to be positive during
second half of the financial year 2017 at the earliest.

Helsinki 20 August 2015

Nexstim Plc

Board of Directors

For further information please visit or contact:
| Nexstim +358 40 8615046 |
| |
| |
|Janne Huhtala, Chief Executive Officer |
| UB Capital Oy (Certified Adviser) +358 9 2538 0225 |
| Walter Ahlström / Tom Olsio |
| Consilium Strategic Communications +44 (0)20 3709 5700 |
| |
| |
|Mary-Jane Elliott / Ivar Milligan |

Publication of financial information

A conference call for media, investors and analysts will take place at 3.00 pm
Finnish time on Thursday 20 August 2015. Janne Huhtala, Chief Executive
Officer, and Mikko Karvinen, Chief Financial Officer, will present the
financial and operational results followed by a Q&A session. The presentation
material will be available on the Nexstim website shortly before the
conference call begins.

The dial-in numbers for the conference call are:

Finland: +358 (0)9 231 95386

Sweden: +46 (0)8 566 19407

UK: +44 (0)1452 557 851

US: +1 86 66 65 40 42

The call ID number is: 89136232

Financial statements release for the year ending 31 December, 2015 will be
published on or about 29 February 2016.

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company
aiming to improve rehabilitation for stroke patients. Nexstim has pioneered
its technology in brain diagnostics with the Navigated Brain Stimulation
(NBS) system as the first and only FDA-cleared and CE-marked navigated
Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of
the motor and speech cortices. Based on the same technology platform, the
company has developed a device for stroke therapy called Navigated Brain
Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III
study at 12 sites in the US aiming to demonstrate the effectiveness of NBT®
and gain FDA clearance for commercialisation in post-acute stroke therapy in
the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq
First North Sweden. For more information please visit

Nexstim Plc's Half-Yearly Report H1 2015


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.